Medpace (NASDAQ:MEDP) (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing. By integrating these disciplines under one roof, the company aims to ensure consistency in trial design, execution and data analysis, while maintaining compliance with international regulatory standards.
Founded in 1992 by Dr. August J. Troendle and headquartered in Cincinnati, Ohio, Medpace has expanded its footprint to serve clients around the world. The company operates facilities and offices across North America, Europe, the Asia-Pacific region and Latin America, enabling it to manage global studies and facilitate site activation in diverse regulatory environments.
Under the leadership of founder and chairman Dr. August J. Troendle, Medpace draws on a multidisciplinary team of scientific, medical and regulatory experts. The company’s management emphasizes close collaboration with sponsors, leveraging therapeutic area specialists and regional capabilities to address the unique challenges of each clinical program and advance patient-focused research.
